Navigating Regulatory Direct-to-Patient Considerations

Clinical trials are undergoing a paradigm shift towards decentralization. Now the participant, rather than site, is at the center of the design and execution of a trial. Direct-to-patient supply is key to enabling clinical trial decentralization, whether partial or full in nature. Enabling DtP requires understanding the regulatory requirements and guidance to streamline planning and ensure a compliant and robust DtP process. This webinar aims to introduce the main regulatory themes, as well as provide a practical insight into converting regulatory theory to practical steps to enable DtP on global studies.